drugset / Trial / NCT05620576

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

NCT05620576

Phase 2 Completed 131 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start
2022-11-14
Primary completion
2023-07-19
Completion
2023-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3857210 Unknown 45 mg Oral